CN111212662A - 治疗癌症的组合疗法 - Google Patents

治疗癌症的组合疗法 Download PDF

Info

Publication number
CN111212662A
CN111212662A CN201880050028.2A CN201880050028A CN111212662A CN 111212662 A CN111212662 A CN 111212662A CN 201880050028 A CN201880050028 A CN 201880050028A CN 111212662 A CN111212662 A CN 111212662A
Authority
CN
China
Prior art keywords
cancer
combination
optionally
cell
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880050028.2A
Other languages
English (en)
Chinese (zh)
Inventor
Y·张
W·魏
陈一友
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keruihua Biotechnology Co Ltd
Original Assignee
Keruihua Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keruihua Biotechnology Co Ltd filed Critical Keruihua Biotechnology Co Ltd
Publication of CN111212662A publication Critical patent/CN111212662A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880050028.2A 2017-06-02 2018-06-01 治疗癌症的组合疗法 Pending CN111212662A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/086911 2017-06-02
PCT/CN2017/086911 WO2018218633A1 (en) 2017-06-02 2017-06-02 Combination therapies for treating cancers
PCT/US2018/035641 WO2018223022A1 (en) 2017-06-02 2018-06-01 Combination therapies for treating cancers

Publications (1)

Publication Number Publication Date
CN111212662A true CN111212662A (zh) 2020-05-29

Family

ID=64454257

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880050028.2A Pending CN111212662A (zh) 2017-06-02 2018-06-01 治疗癌症的组合疗法

Country Status (10)

Country Link
US (2) US12076399B2 (https=)
EP (1) EP3630196A4 (https=)
JP (1) JP2020522521A (https=)
KR (1) KR20200011957A (https=)
CN (1) CN111212662A (https=)
AU (1) AU2018275118B2 (https=)
BR (1) BR112019025453A2 (https=)
CA (1) CA3063743A1 (https=)
RU (1) RU2019143403A (https=)
WO (2) WO2018218633A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114939168A (zh) * 2022-05-16 2022-08-26 复旦大学 Cdk6抑制剂在制备预防或治疗垂体腺瘤的药物中的应用
CN115029316A (zh) * 2022-06-20 2022-09-09 华中科技大学同济医学院附属协和医院 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
MX2020007312A (es) 2018-01-08 2021-01-08 G1 Therapeutics Inc Regimenes de dosificacion superior de g1t38.
IL257225A (en) * 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
US11633401B2 (en) 2018-07-06 2023-04-25 Memorial Sloan Kettering Cancer Center Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer
WO2020036852A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
WO2021068868A1 (en) * 2019-10-09 2021-04-15 Cothera Bioscience, Inc. Combination therapy for cancers with kras mutation
AU2020363100A1 (en) * 2019-10-09 2022-05-12 Cothera Bioscience, Inc. Combination therapy for cancers with KRAS mutation
CN112168828A (zh) * 2020-11-10 2021-01-05 南京医科大学 一种egfr与cdk4/6小分子靶向药组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US20170027951A1 (en) * 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
CN106456774A (zh) * 2014-04-04 2017-02-22 阿斯利康(瑞典)有限公司 Nras突变的癌症的治疗中使用的egfr抑制剂及mek抑制剂的组合
WO2017037576A1 (en) * 2015-08-28 2017-03-09 Novartis Ag Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
WO2017070475A1 (en) * 2015-10-22 2017-04-27 Merrimack Pharmaceuticals, Inc. Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965362A (en) 1992-03-04 1999-10-12 The Regents Of The University Of California Comparative genomic hybridization (CGH)
CZ292061B6 (cs) 1994-03-17 2003-07-16 Merck Patent Gmbh Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
WO2001060803A1 (en) 2000-02-15 2001-08-23 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazolium derivatives
ES2398099T3 (es) 2001-02-19 2013-03-13 Merck Patent Gmbh Anticuerpos anti-EGFR modificados con inmunogenicidad reducida
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
NZ530212A (en) 2001-06-13 2006-09-29 Genmab As An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
CN100343248C (zh) 2003-04-15 2007-10-17 安斯泰来制药株式会社 溴化物及其晶体
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
CA2561516A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005111213A1 (ja) 2004-05-18 2005-11-24 Kurume University Ｍｙｃ標的遺伝子mimitin
WO2006036941A2 (en) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors
WO2007058823A2 (en) 2005-11-12 2007-05-24 Eli Lilly And Company Anti-egfr antibodies
WO2007086342A1 (ja) 2006-01-27 2007-08-02 National University Corporation Chiba University c-myc遺伝子転写抑制因子FIRのスプライシングバリアント又はイントロン２内の４塩基繰り返し配列による癌検出方法
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
CA2661618A1 (en) 2006-08-25 2008-02-28 Astellas Pharma Inc. Stabilized pharmaceutical composition
MX2009004785A (es) 2006-10-31 2009-06-05 Schering Corp Amidas 2-aminotiazol-4-carboxilicas como inhibidores de proteina quinasa.
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
CN101910167A (zh) 2007-10-29 2010-12-08 先灵公司 噻唑甲酰胺衍生物及其治疗癌症
WO2009064675A1 (en) 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
WO2010056931A1 (en) 2008-11-14 2010-05-20 Intelligent Oncotherapeutics, Inc. Methods for identification of tumor phenotype and treatment
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
EP3028699B1 (en) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2011130232A1 (en) 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
JP2014156400A (ja) 2011-05-24 2014-08-28 Astellas Pharma Inc 腫瘍の画像診断用標識誘導体
WO2012167099A1 (en) 2011-06-01 2012-12-06 Baylor College Of Medicine Biomarkers and therapy for cancer
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
US20130122005A1 (en) 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
EP2780354A4 (en) 2011-11-16 2015-06-24 Oncomed Pharm Inc HUMAN NOTCH RECEPTOR MUTATIONS AND THEIR USE
US9662329B2 (en) 2012-03-26 2017-05-30 University of Pittsburgh—of the Commonwealth System of Higher Education Use of survivin antagonists in polyomavirus-related disease
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
SG10201907684PA (en) 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
US20160024591A1 (en) 2013-03-14 2016-01-28 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
JP2016515132A (ja) * 2013-03-14 2016-05-26 ジェネンテック， インコーポレイテッド Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
SG10201706210WA (en) 2013-03-15 2017-09-28 Genentech Inc Compositions and methods for diagnosis and treatment of hepatic cancers
UA118846C2 (uk) * 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
US9314460B1 (en) 2013-04-09 2016-04-19 Stc.Unm Method for cancer cell reprogramming
KR101514877B1 (ko) 2013-05-06 2015-04-24 조선대학교산학협력단 ＡＰＥ/Ｒｅｆ -1 및 ＪＡＧ1/Ｎｏｔｃｈ의 대장암 진단용 마커로서의 용도
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
AU2014368927B2 (en) 2013-12-20 2018-10-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
ES2686549T3 (es) 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
US9446148B2 (en) * 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CN107801378A (zh) * 2015-05-22 2018-03-13 普莱希科公司 用于治疗braf‑v600相关的疾病的plx‑8394或plx‑7904
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
WO2017040990A1 (en) * 2015-09-03 2017-03-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CA2998472A1 (en) 2015-09-15 2017-03-23 Swedish Health Services Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof
AU2017205478A1 (en) 2016-01-07 2018-06-28 Swadesh K. Das A method of modulating survival and stemness of cancer stem cells by MDA-9/Syntenin (SDCBP)
US11311540B2 (en) 2016-02-17 2022-04-26 Acetylon Pharmaceuticals, Inc. Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs
TW201813644A (zh) 2016-09-23 2018-04-16 江蘇恆瑞醫藥股份有限公司 酪胺酸激酶抑制劑在製備治療癌症藥物中的用途
WO2018127786A1 (en) 2017-01-06 2018-07-12 Oslo Universitetssykehus Hf Compositions and methods for determining a treatment course of action
CN106822905B (zh) 2017-03-08 2019-05-17 暨南大学 含Survivin抑制剂和IRE1抑制剂的药物及用途
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
US12571049B2 (en) 2018-03-21 2026-03-10 Dana-Farber Cancer Institute, Inc. Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2020034061A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co., Ltd. Biomarkers for cancer therapy
WO2020097901A1 (en) 2018-11-16 2020-05-22 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
WO2020036852A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456774A (zh) * 2014-04-04 2017-02-22 阿斯利康(瑞典)有限公司 Nras突变的癌症的治疗中使用的egfr抑制剂及mek抑制剂的组合
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US20170027951A1 (en) * 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
WO2017037576A1 (en) * 2015-08-28 2017-03-09 Novartis Ag Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
WO2017070475A1 (en) * 2015-10-22 2017-04-27 Merrimack Pharmaceuticals, Inc. Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114939168A (zh) * 2022-05-16 2022-08-26 复旦大学 Cdk6抑制剂在制备预防或治疗垂体腺瘤的药物中的应用
CN115029316A (zh) * 2022-06-20 2022-09-09 华中科技大学同济医学院附属协和医院 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用
CN115029316B (zh) * 2022-06-20 2024-04-30 华中科技大学同济医学院附属协和医院 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用

Also Published As

Publication number Publication date
KR20200011957A (ko) 2020-02-04
EP3630196A4 (en) 2021-02-24
WO2018223022A1 (en) 2018-12-06
US12076399B2 (en) 2024-09-03
RU2019143403A (ru) 2021-07-13
JP2020522521A (ja) 2020-07-30
RU2019143403A3 (https=) 2021-10-01
CA3063743A1 (en) 2018-12-06
US20200147211A1 (en) 2020-05-14
WO2018218633A1 (en) 2018-12-06
BR112019025453A2 (pt) 2020-06-23
AU2018275118B2 (en) 2024-12-19
AU2018275118A1 (en) 2019-12-19
EP3630196A1 (en) 2020-04-08
US20250121057A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
US20250121057A1 (en) Combination therapies for treating cancers
CN111971062B (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
US20220162332A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof
JP6788600B2 (ja) がんを治療するための、ｐｄ−１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
US20230203202A1 (en) Proteins binding nkg2d, cd16 and 5t4
JP7829605B2 (ja) コネキシン４３抗体およびその使用
JP2023500575A (ja) 癌を治療するためのＰＤ－１アンタゴニスト、ＶＥＧＦＲ／ＦＧＦＲ／ＲＥＴチロシンキナーゼ阻害剤、及びＣＢＰ／β－カテニン阻害剤の組合せ
CN116323657B (zh) 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
CN120437318A (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
WO2025082449A1 (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
HK40029586A (en) Combination therapies for treating cancers
CN113842456B (zh) 一种抗人4-1bb的单克隆抗体制剂及其用途
JP2019505516A (ja) インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
HK40100613A (zh) 连接蛋白43抗体及其用途
CN121693347A (zh) 使用可活化抗ctla4抗体与pembrolizumab组合治疗癌症的方法
JP2025529121A (ja) 抗ｃｔｌａ４抗体を用いたがんの治療方法
TW202527984A (zh) 5t4抗體藥物結合物及其使用之方法
WO2024213081A1 (zh) 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途
CN121399156A (zh) 使用抗cd47抗体治疗晚期或转移性实体癌的方法
HK40042791A (en) Connexin 43 antibodies and use thereof
EA046745B1 (ru) Способ лечения рака активируемым антителом против pdl1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029586

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200529